Elidel (Pimecrolimus)
Topical calcineurin inhibitor for atopic eczema
Quick Facts About Elidel
Key Takeaways About Elidel
- Steroid-free treatment: Elidel is a non-steroidal anti-inflammatory cream, meaning it does not cause skin thinning or other steroid-related side effects
- Safe for sensitive areas: Can be used on the face, neck, and skin folds where topical corticosteroids are often avoided
- Apply twice daily: Use a thin layer morning and evening on affected areas only, and combine with regular moisturizer use
- Early intervention helps: Applying Elidel at the first sign of itching or redness can prevent eczema flare-ups from developing
- Sun protection needed: Avoid excessive sun exposure during treatment; wear protective clothing and use sunscreen when outdoors
What Is Elidel and What Is It Used For?
Elidel cream contains pimecrolimus, a topical calcineurin inhibitor that treats mild to moderate atopic eczema (atopic dermatitis) in children from 3 months of age and adults. It is steroid-free and works by targeting the immune cells responsible for skin inflammation.
Elidel cream was specifically developed to treat the inflammatory skin condition known as atopic eczema, also called atopic dermatitis. This chronic condition affects approximately 10-20% of children and 2-5% of adults worldwide, causing persistent itching, redness, dryness, and sometimes cracking or weeping of the skin. The active ingredient, pimecrolimus, belongs to a class of medicines known as topical calcineurin inhibitors (TCIs), which represent an important alternative to traditional topical corticosteroids.
Pimecrolimus works by selectively binding to macrophilin-12, an intracellular protein found in immune cells. This binding inhibits the enzyme calcineurin, which normally plays a key role in activating T-cells and triggering the release of pro-inflammatory cytokines such as interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon-gamma (IFN-γ). By blocking this pathway, pimecrolimus reduces the inflammatory cascade that causes the characteristic symptoms of atopic eczema — itching, redness, swelling, and skin thickening.
A significant advantage of Elidel over topical corticosteroids is that it does not cause skin atrophy (thinning), telangiectasia (visible blood vessels), or striae (stretch marks), even with prolonged use. This makes it particularly valuable for treating eczema on sensitive areas such as the face, eyelids, neck, and skin folds (intertriginous areas), where corticosteroid-induced skin damage is a major concern. Studies have demonstrated that long-term use of pimecrolimus maintains normal skin structure and collagen synthesis.
Elidel is indicated as a second-line treatment for atopic eczema when other approaches such as regular emollient therapy have not provided adequate relief, or when a healthcare provider determines that the patient should avoid long-term topical corticosteroid therapy. If applied at the first signs of a flare-up — when itching or redness begins — Elidel can help prevent the eczema from progressing and reduce the overall need for rescue treatment with corticosteroids.
If you see no improvement after 6 weeks of using Elidel, or if your eczema worsens during treatment, speak to your doctor. They may need to reassess the diagnosis or consider alternative treatment strategies.
What Should You Know Before Using Elidel?
Before using Elidel, inform your doctor about any immunodeficiency conditions, active skin infections, or if you are pregnant or breastfeeding. Elidel should only be used for atopic eczema and should not be applied to areas with active viral infections such as cold sores or chickenpox.
Contraindications
Do not use Elidel cream if you are allergic to pimecrolimus or any of the other ingredients in the product. The inactive ingredients include medium-chain triglycerides, oleyl alcohol, propylene glycol, stearyl alcohol, cetyl alcohol, benzyl alcohol, citric acid anhydrous, sodium hydroxide, and purified water. If you have previously experienced a reaction to any of these excipients, inform your doctor before starting treatment.
Warnings and Precautions
Speak to your doctor before using Elidel if your immune system is compromised for any reason, including conditions such as HIV/AIDS, immunodeficiency syndromes, or if you are receiving immunosuppressive therapy. Elidel should only be used to treat atopic eczema and must not be applied to other skin conditions.
Elidel is for external use only and must not be applied in or near the nose, eyes, or mouth. If the cream accidentally comes into contact with these areas, wipe it off carefully and rinse thoroughly with water. Be particularly careful not to transfer the cream to the mouth via the hands, especially when treating young children.
- Active viral infections: Do not apply Elidel to skin areas affected by active viral infections such as cold sores (herpes simplex) or chickenpox (varicella). Pimecrolimus may interfere with the local immune response needed to combat these infections.
- Skin infections: If you have a bacterial or fungal skin infection, consult your doctor before using Elidel. Your doctor may prescribe appropriate antimicrobial treatment first. Once the infection has fully cleared, you can begin or resume Elidel treatment. If a skin infection develops during Elidel use, contact your doctor.
- Eczema herpeticum: Treatment with Elidel may carry an increased risk of developing a serious herpes simplex skin infection known as eczema herpeticum. Contact your doctor immediately if you develop painful sores on your body, and stop using Elidel until the infection has completely resolved.
- Sun exposure: Avoid excessive sunlight, sunlamps, and tanning beds while using Elidel. When outdoors after applying the cream, wear loose-fitting protective clothing, use appropriate sunscreen, and limit sun exposure.
- Occlusive dressings: Do not cover the treated skin with bandages or dressings. Normal clothing can be worn as usual over the treated areas.
- Lymph node swelling: If your lymph nodes become swollen during treatment with Elidel, contact your doctor for evaluation.
- Erythroderma and Netherton syndrome: If you have generalized redness of the entire body (erythroderma) or a skin condition called Netherton syndrome, consult your doctor before using Elidel, as increased systemic absorption may occur.
- Skin tumours: Discuss with your doctor before using Elidel if you have any pre-existing skin tumour or malignancy.
Use in Children
Elidel is approved for use in children aged 3 months and older for the treatment of mild to moderate atopic eczema. It is not recommended for infants under 3 months of age, as there is insufficient clinical data in this age group. Clinical trials have shown that pimecrolimus 1% cream is effective and well-tolerated in children, with a safety profile comparable to that seen in adults. Parents and caregivers should apply the cream under medical supervision and follow the prescribed treatment regimen carefully.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Elidel. The cream should not be used during pregnancy unless clearly necessary and prescribed by a healthcare professional. There are no adequate and well-controlled studies of Elidel in pregnant women, and the potential risk to the developing foetus is unknown.
It is not known whether pimecrolimus passes into breast milk when applied to the skin. If you are breastfeeding, do not apply Elidel to the breast area. Discuss the benefits and risks of using Elidel while breastfeeding with your doctor.
Alcohol
In rare cases, facial flushing, rash, burning sensation, itching, or swelling may occur shortly after consuming alcohol while using Elidel cream. If you experience these symptoms, they are typically mild and resolve on their own.
Elidel cream contains cetyl alcohol and stearyl alcohol, which may cause local skin reactions such as contact dermatitis. It also contains 10 mg of benzyl alcohol per gram of cream, which may cause allergic reactions and mild local irritation. Additionally, it contains 50 mg of propylene glycol (E1520) per gram, which may cause skin irritation in some individuals.
How Does Elidel Interact with Other Drugs?
Because pimecrolimus is applied topically and has very low systemic absorption, drug interactions with Elidel are generally unlikely. However, it should not be used concurrently with UV light therapy or systemic immunosuppressants. Avoid applying the cream to vaccination sites while a local reaction persists.
Pimecrolimus is applied directly to the skin and has minimal systemic absorption, which significantly reduces the potential for drug interactions compared to oral medications. However, certain precautions should still be observed to ensure safe and effective treatment.
Vaccinations
Application of Elidel to skin areas where a vaccine has been administered is not recommended while a local reaction from the vaccination persists. If you have extensive atopic eczema, your doctor may advise you to discontinue Elidel temporarily before receiving a vaccination. Consult your healthcare provider for specific guidance on the timing of vaccinations in relation to your Elidel treatment.
Significant Interactions
| Interacting Agent | Type | Effect / Recommendation |
|---|---|---|
| UV light therapy (UVA, PUVA, UVB) | Contraindicated combination | Do not use Elidel concurrently with phototherapy. The safety of combined use has not been established. |
| Systemic immunosuppressants (e.g. azathioprine, ciclosporin) | Contraindicated combination | Do not use Elidel concurrently with oral or injectable immunosuppressants. May increase overall immunosuppressive effects. |
| CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole) | Theoretical interaction | Pimecrolimus is metabolised by CYP3A4. Although systemic absorption is low, caution is advised in patients taking potent CYP3A4 inhibitors, particularly if extensive areas are treated. |
| Topical corticosteroids | Sequential use acceptable | Topical corticosteroids may be used as needed for acute flares. Elidel can be used for maintenance once the flare is controlled. |
| Emollients (moisturisers) | Safe to combine | Apply emollients directly after Elidel. Regular use of emollients is encouraged as part of comprehensive eczema management. |
| Vaccines (live or inactivated) | Precaution | Avoid applying Elidel to vaccination sites with active local reactions. Consider temporary discontinuation before vaccination if extensive eczema is present. |
It is generally considered unlikely that Elidel interacts significantly with most systemically administered medications. However, always inform your doctor or pharmacist about all medicines you are currently using, have recently used, or might use, including over-the-counter products and herbal supplements.
Driving and Operating Machinery
Elidel has no known effect on the ability to drive or use machines. You can safely carry out these activities while using the cream.
What Is the Correct Dosage of Elidel?
Elidel cream should be applied as a thin layer to the affected skin areas twice daily, once in the morning and once in the evening. It can be used on all skin surfaces including the face and skin folds. Treatment should be intermittent, not continuous, and should stop when symptoms resolve.
Always use Elidel exactly as your doctor or pharmacist has instructed. The cream is applied to the affected areas only — not to unaffected skin. A thin layer should cover the eczema patches completely, and the cream should be gently rubbed in until fully absorbed.
How to Apply Elidel
- Wash and dry your hands thoroughly before application.
- Open the tube. (The first time you use a new tube, break the seal using the pointed tip on top of the cap.)
- Squeeze a small amount of cream onto your finger.
- Apply a thin layer of Elidel only to the skin areas with eczema, ensuring complete coverage of the affected area.
- Gently rub the cream in completely.
- Replace the cap on the tube.
Adults
Standard Adult Dosage
Apply a thin layer of Elidel cream (10 mg/g) to the affected skin areas twice daily (morning and evening). You may apply emollient (moisturiser) immediately after Elidel. The cream can be used on all skin surfaces, including the head, face, neck, and skin folds. Treatment duration should be as prescribed by your doctor.
Children (3 months and older)
Paediatric Dosage
The same dosage applies as for adults: a thin layer applied to affected skin areas twice daily. Elidel is approved for children from 3 months of age. It is not recommended for infants under 3 months. Particular care should be taken to prevent the child from ingesting the cream, especially when applied to the hands or areas near the mouth.
Elderly
Dosage in Older Adults
No dose adjustment is required for elderly patients. Apply the same twice-daily regimen as described for adults. Elderly patients should be monitored for skin infections and any changes in skin condition during treatment.
| Patient Group | Dosage | Frequency | Notes |
|---|---|---|---|
| Adults | Thin layer to affected areas | Twice daily (morning & evening) | Can use on all skin surfaces including face |
| Children (3 months – 17 years) | Thin layer to affected areas | Twice daily (morning & evening) | Prevent ingestion; supervise application |
| Infants (<3 months) | Not recommended | N/A | Insufficient data in this age group |
| Elderly | Thin layer to affected areas | Twice daily (morning & evening) | No dose adjustment needed |
Treatment Duration
Long-term treatment with Elidel should be intermittent, not continuous. Discontinue use once the signs and symptoms of eczema have resolved. For proactive management, restart treatment at the first signs of recurrence — itching or redness — to prevent a full flare-up. This approach has been shown to improve long-term eczema control and reduce the overall burden of disease. Use Elidel for as long as your doctor prescribes, and seek medical advice if there is no improvement after 6 weeks or if the condition worsens.
Missed Dose
If you forget to apply Elidel, apply it as soon as you remember and then continue with your regular schedule. If it is almost time for the next application, skip the missed dose and continue as normal. Do not apply extra cream to compensate for a missed dose.
Overdose
If you accidentally apply too much Elidel, simply wipe off the excess cream. No serious effects are expected from topical overuse. If Elidel cream is accidentally swallowed, contact your doctor or a poison control centre immediately.
Do not bathe, shower, or swim immediately after applying Elidel, as the cream may be washed off before it can be absorbed. You may use emollients directly after applying Elidel to maintain skin hydration.
What Are the Side Effects of Elidel?
The most common side effect of Elidel is a transient burning or warm sensation at the application site, which usually occurs at the start of treatment and resolves as the skin heals. Serious side effects such as angioedema or anaphylaxis are very rare.
Like all medicines, Elidel can cause side effects, although not everyone experiences them. The most frequently reported side effect is a mild to moderate burning or warm sensation at the application site, which is typically transient and tends to decrease as the eczema improves. Side effects are classified below by their frequency of occurrence.
Very Common
May affect more than 1 in 10 people
- Transient warmth and/or burning sensation at the application site
Common
May affect up to 1 in 10 people
- Irritation, itching, and redness at the application site
- Skin infections, e.g. folliculitis (inflammation of hair follicles, may cause small blisters with pus)
Uncommon
May affect up to 1 in 100 people
- Skin infections: impetigo, cold sores (herpes simplex), shingles (herpes zoster), eczema herpeticum, molluscum contagiosum, warts, boils
- Local skin reactions: rash, pain, stinging sensation, mild skin peeling, dryness, swelling, or worsening of eczema symptoms
Rare and Very Rare
May affect up to 1 in 1,000 people (rare) or fewer (very rare)
- Angioedema (rare): itching, hives (urticaria), red rash on hands, feet and throat, swelling of throat and tongue, swelling around eyes and lips, difficulty breathing and swallowing
- Anaphylactic reaction (very rare): flushing with red itchy skin, swelling of hands, feet, ankles, face, lips, mouth and throat, difficulty swallowing or breathing, feeling faint
- Facial flushing, rash, burning sensation, itching, or swelling shortly after alcohol consumption
- Skin discolouration at the application site (may become lighter or darker)
If you experience signs of angioedema (swelling of the face, lips, tongue, or throat with difficulty breathing or swallowing) or anaphylaxis shortly after applying Elidel, stop using the cream immediately and seek emergency medical care.
Cases of malignancies including lymphoma and skin cancer have been reported in patients using Elidel. However, a causal relationship has not been established. Cases of enlarged lymph nodes (lymphadenopathy) have also been reported during treatment, though no causal link has been confirmed. If you notice any unusual lumps or changes in your lymph nodes, inform your doctor.
If any side effects become severe, or if you notice any effects not listed in this information, contact your doctor or pharmacist. Reporting suspected adverse reactions after a medicine has been authorised is important, as it allows continued monitoring of the benefit/risk balance of the medicine.
How Should You Store Elidel?
Store Elidel cream at or below 25°C (77°F). Do not freeze. Keep the tube tightly closed in its original packaging. Once opened, use within 12 months. Keep out of the sight and reach of children.
Proper storage of Elidel cream is essential to maintain its effectiveness and safety throughout the treatment period. Store the product in its original carton to protect it from light and environmental contamination.
- Temperature: Store at or below 25°C (77°F). Do not freeze the cream, as this may alter its consistency and effectiveness.
- Packaging: Keep the cream in its original carton. Close the tube tightly after each use to prevent contamination and drying out.
- Shelf life after opening: An opened tube should be used within 12 months. It may be helpful to write the date of opening on the carton.
- Expiry date: Do not use Elidel after the expiry date printed on the carton and tube. The expiry date refers to the last day of that month.
- Children: Store this medicine out of the sight and reach of children.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment.
What Does Elidel Contain?
Each gram of Elidel cream contains 10 mg of pimecrolimus as the active ingredient. The cream is a white, odourless formulation that does not stain and is easily absorbed into the skin.
Active Ingredient
The active substance is pimecrolimus. Each gram (1 g) of Elidel cream contains 10 mg of pimecrolimus (equivalent to 1% w/w concentration). Pimecrolimus is a 33-epi-chloro derivative of the macrolactam ascomycin, structurally related to tacrolimus but with greater selectivity for the skin.
Inactive Ingredients (Excipients)
The other ingredients in Elidel cream are:
- Medium-chain triglycerides
- Oleyl alcohol
- Propylene glycol (E1520) — 50 mg per gram of cream
- Stearyl alcohol
- Cetyl alcohol
- Mono- and diglycerides
- Sodium cetostearyl sulfate
- Benzyl alcohol — 10 mg per gram of cream
- Citric acid anhydrous
- Sodium hydroxide
- Purified water
Appearance and Pack Sizes
Elidel is a white, odourless cream that does not stain clothing and can be easily rubbed into the skin. It is available in tube sizes of 5 g, 15 g, 30 g, 60 g, and 100 g. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Elidel
Elidel cream contains pimecrolimus and is used to treat mild to moderate atopic eczema (atopic dermatitis) in both children aged 3 months and older and adults. It is a non-steroidal cream that works by suppressing the inflammatory immune response in the skin. It is typically used when emollients alone are insufficient or when a doctor recommends avoiding topical corticosteroids, particularly for sensitive areas like the face and skin folds.
No, Elidel is not a steroid. It belongs to a class of medicines called topical calcineurin inhibitors (TCIs). Unlike corticosteroids, Elidel does not cause skin thinning (atrophy), stretch marks (striae), or other steroid-related side effects. This makes it particularly useful for long-term treatment and for sensitive areas such as the face, neck, and skin folds.
Many patients notice improvement within the first 1–2 weeks of treatment, particularly in reduced itching. However, full improvement may take several weeks. If no improvement is seen after 6 weeks, consult your doctor to reassess the treatment plan. For best results, apply Elidel at the first sign of itching or redness to prevent full flare-ups.
Yes, Elidel cream can be used on all skin surfaces including the face, head, neck, and skin folds. This is one of its key advantages over topical corticosteroids, which carry a risk of skin thinning when used on delicate facial skin. Elidel does not cause skin atrophy, making it well-suited for these sensitive areas.
Elidel is approved for children aged 3 months and older with mild to moderate atopic eczema. It is not recommended for infants under 3 months. Clinical studies have demonstrated its effectiveness and safety in the paediatric population. Parents should supervise application and take care to prevent the child from ingesting the cream, particularly when applied to the hands or face.
Yes, you can and should use emollients (moisturisers) as part of your eczema management alongside Elidel. Apply the emollient immediately after applying Elidel. However, avoid bathing, showering, or swimming right after applying the cream, as it may be washed off before proper absorption.
References
This article is based on the following internationally recognised medical sources and peer-reviewed research:
- European Medicines Agency (EMA). Elidel — Summary of Product Characteristics (SmPC). EMA/CHMP. Available at: www.ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Elidel (pimecrolimus) Cream, 1% — Prescribing Information. FDA. Available at: www.accessdata.fda.gov.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi:10.1111/jdv.14891.
- Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758-766.
- Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi:10.1542/peds.2014-1990.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023.
- National Institute for Health and Care Excellence (NICE). Pimecrolimus: topical eczema treatment. NICE British National Formulary (BNF). Available at: bnf.nice.org.uk.
- World Health Organization (WHO). WHO Model Formulary: Dermatological preparations. WHO. Available at: www.who.int.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and pharmacists with specialist expertise in dermatology, pharmacology, and evidence-based medicine.
All content is reviewed by board-certified physicians following international medical guidelines (EMA, FDA, NICE) and the GRADE evidence framework.
Evidence Level 1A. No commercial funding or pharmaceutical sponsorship. Independent medical editorial content.